secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001193125-24-138898
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica amends Torii deal: jointly fund Phase 3 common-warts trial; gets $8M milestone, issues warrant
--------------------------------------------------------------------------------

- Amendment equally splits cost of global Phase 3 trial of YCANTH for common warts; Torii funds upfront, Verrica repays half with interest (SOFR+2% min 6%).
- Torii to pay $8M milestone upon first patient dosed in Japan; trial expected to start H1 2025.
- Verrica issues warrant for 500,000 shares at $9.56, vesting on trial milestones (first dose, database lock, NDA submission).
- Common warts affects ~22M patients in U.S. with no FDA-approved therapies; Verrica sees multi-billion opportunity.
- Torii may invoice Verrica if not repaid within 60 months; termination tied to trial progress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524138898/0001193125-24-138898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312524138898/d828339d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-138898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer